Pieris Pharmaceuticals, Inc. - Common Stock (NQ:PIRS)

13.60 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pieris Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023

March 24, 2023

Via ACCESSWIRE

12 Health Care Stocks Moving In Friday's After-Market Session ↗

March 17, 2023

Via Benzinga

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)

January 10, 2023

Via ACCESSWIRE

Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference

November 23, 2022

Via ACCESSWIRE

Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference

November 09, 2022

Via ACCESSWIRE

Recap: Pieris Pharmaceuticals Q3 Earnings ↗

November 02, 2022

Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 02, 2022

Via ACCESSWIRE

Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate ↗

August 24, 2022

Via Benzinga

Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

November 01, 2022

Via ACCESSWIRE

Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022

October 26, 2022

Via ACCESSWIRE

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 11, 2022

Gainers DICE Therapeutics (NASDAQ:DICE) stock moved upwards by 83.4% to $45.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.7 billion.

Via Benzinga

Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 08, 2022

Via ACCESSWIRE

Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 04, 2022

Via ACCESSWIRE

Recap: Pieris Pharmaceuticals Q1 Earnings ↗

May 11, 2022

Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For May 11, 2022 ↗

May 11, 2022

Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.

Via Benzinga

Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS

August 24, 2022

Via ACCESSWIRE

Pieris Pharmaceuticals's Return On Capital Employed Insights ↗

August 19, 2022

Benzinga Pro data, Pieris Pharmaceuticals (NASDAQ:PIRS) reported Q2 sales of $3.70 million. Earnings fell to a loss of $10.34 million, resulting in a 102.67% decrease from last quarter.

Via Benzinga

Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs ↗

August 04, 2022

Via Benzinga

Pieris Pharmaceuticals: Q2 Earnings Insights ↗

August 04, 2022

Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Pieris Pharmaceuticals's Earnings Outlook ↗

August 03, 2022

Pieris Pharmaceuticals (NASDAQ:PIRS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022

July 28, 2022

BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022

July 28, 2022

Via ACCESSWIRE

Pieris Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

June 15, 2022

According to Benzinga Pro data, during Q1, Pieris Pharmaceuticals (NASDAQ:PIRS) posted sales of $10.99 million. Earnings were up 46.49%, but Pieris Pharmaceuticals still reported an overall loss of...

Via Benzinga

Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

June 02, 2022

BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

May 18, 2022

BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

4 Stocks Under $3 Insiders Are Aggressively Buying ↗

May 17, 2022

US crude oil futures traded slightly lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or...

Via Benzinga

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗

May 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 11, 2022

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT BOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

Pieris Pharmaceuticals's Earnings Outlook ↗

May 10, 2022

Pieris Pharmaceuticals (NASDAQ:PIRS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022

May 04, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

From Pieris Pharmaceuticals, Inc.

Via AccessWire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.